NTRA insider trading
NasdaqGS HealthcareNatera, Inc.: insider trade history from SEC Form 4 filings.
About Natera, Inc.
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Company website: www.natera.com
NTRA insider activity at a glance
FilingIQ tracks 3,102 insider transactions for NTRA in filings since Jul 7, 2015. The most recent transaction is dated Oct 1, 2026.
Across the full history, 15 open-market purchases
and 1,843 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on NTRA insider trades is 61.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest NTRA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading NTRA
13F funds holding NTRA
Frequently asked
- How many insider trades does FilingIQ track for NTRA?
- FilingIQ tracks 3,102 Form 4 insider transactions for NTRA (Natera, Inc.), covering filings from Jul 7, 2015 onwards. 129 of those are dated within the last 90 days.
- Are NTRA insiders net buyers or net sellers?
- Across the full Form 4 history for NTRA, 15 transactions (0%) were open-market purchases and 1,843 (59%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does NTRA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is NTRA in?
- Natera, Inc. (NTRA) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $29.41B.
Methodology & sources
Every NTRA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.